Benzinga | Jan 7, 2022 01:03PM EST

JMP Securities Maintains Market Outperform on Intellia Therapeutics, Lowers Price Target to $165

JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and lowers the price target from $175 to $165.